Mature T-cell and NK-cell lymphoma involvement of the central nervous system: a single center experience

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265–276. doi:10.1182/blood-2005-06-2508
   PubMed Web of Science ®Google Scholar
• Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1997;8(6):583–592. doi:10.1023/a:1008200307625
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253. doi:10.1182/blood.2022015851
   PubMed Web of Science ®Google Scholar
• Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the Front-Line treatment of patients with CD30+ peripheral T-Cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137–3143. doi:10.1200/JCO.2013.54.2456
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240. doi:10.1016/S0140-6736(18)32984-2
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Falchi L, Lue JK, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with ptcl: a multicenter phase I study. Blood. 2019;134(17):1395–1405. doi:10.1182/blood.2019001285
   PubMed Web of Science ®Google Scholar
• Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131(4):397–407. doi:10.1182/blood-2017-09-806737
   PubMed Web of Science ®Google Scholar
• Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161–2170. doi:10.1182/blood.2020009004
   PubMed Web of Science ®Google Scholar
• Stuver RN, Khan N, Schwartz M, et al. Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry. Am J Hematol. 2019;94(6):641–649. doi:10.1002/ajh.25463
   PubMed Web of Science ®Google Scholar
• Ma H, Cheng B, Falchi L, et al. Survival benefit in patients with peripheral T‐cell lymphomas after treatments with novel therapies and clinical trials. Hematol Oncol. 2020;38(1):51–58. doi:10.1002/hon.2705
   PubMed Web of Science ®Google Scholar
• Choi JS, Nam DH, Ko YH, et al. Primary Central nervous system lymphoma in korea: comparison of B- and T-cell lymphomas. Am J Surg Pathol. 2003;27(7):919–928. doi:10.1097/00000478-200307000-00007
   PubMed Web of Science ®Google Scholar
• Mocikova H, Pytlik R, Benesova K, et al. Peripheral T-Cell lymphomas involving the Central nervous system: a report from the czech lymphoma study group registry. Front Oncol. 2022;12:874462. doi:10.3389/fonc.2022.874462
   PubMed Web of Science ®Google Scholar
• Ellin F, Landström J, Jerkeman M, et al. Central nervous system relapse in peripheral T-cell lymphomas: a swedish lymphoma registry study. Blood. 2015;126(1):36–41. doi:10.1182/blood-2014-12-616961
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-Cell lymphoma after first relapse or progression: spectrum of disease and rare Long-Term survivors. J Clin Oncol. 2013;31(16):1970–1976. doi:10.1200/JCO.2012.44.7524
   PubMed Web of Science ®Google Scholar
• Menon MP, Nicolae A, Meeker H, et al. Primary CNS T-cell lymphomas: a clinical, morphologic, immunophenotypic, and molecular analysis. Am J Surg Pathol. 2015;39(12):1719–1729. doi:10.1097/PAS.0000000000000503
   PubMed Web of Science ®Google Scholar
• Gurion R, Mehta N, Migliacci JC, et al. Central nervous system involvement in T-cell lymphoma: a single center experience. Acta Oncol. 2016;55(5):561–566. doi:10.3109/0284186X.2015.1118656
   PubMed Web of Science ®Google Scholar
• Hayabuchi N, Shibamoto Y, Onizuka Y. Primary Central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys. 1999;44(2):265–272. doi:10.1016/s0360-3016(98)00564-1
   PubMed Web of Science ®Google Scholar
• Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467–1475. doi:10.1093/annonc/mdh392
   PubMed Web of Science ®Google Scholar
• Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood. 2010;115(26):5427. doi:10.1182/blood-2010-02-266890
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516 – the southwest oncology group. J Clin Oncol. 2009;27(1):114–119. doi:10.1200/JCO.2008.16.8021
   PubMed Web of Science ®Google Scholar
• Kim SJ, Oh SY, Hong JY, et al. When do we need Central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010;21(5):1058–1063. doi:10.1093/annonc/mdp412
   PubMed Web of Science ®Google Scholar
• Yi JH, Kim JH, Baek KK, et al. Elevated LDH and paranasal sinus involvement are risk factors for Central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1636–1643. doi:10.1093/annonc/mdq645
   PubMed Web of Science ®Google Scholar
• Chihara D, Fanale MA, Miranda RN, et al. The risk of Central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018;13(3):e0191461. doi:10.1371/journal.pone.0191461
   PubMed Web of Science ®Google Scholar
• Bhansali RS, Ellin F, Cao M, et al. CNS relapse in T-Cell lymphoma index: a risk score to predict Central nervous system relapse in patients with T-Cell lymphomas. Blood. 2022;140(Supplement 1):1481–1484. doi:10.1182/blood-2022-160090
   Google Scholar
• Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16(3):864–871. doi:10.1200/JCO.1998.16.3.864
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Blay JY, O'Neill BP, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005;23(10):2233–2239. doi:10.1200/JCO.2005.07.109
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Donadoni G, Cabras MG, et al. High doses of antimetabolites followed by High-Dose sequential chemoimmunotherapy and autologous Stem-Cell transplantation in patients with systemic B-Cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015;33(33):3903–3910. doi:10.1200/JCO.2015.61.1236
   PubMed Web of Science ®Google Scholar
• Korfel A, Elter T, Thiel E, et al. Phase II study of Central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364–370. doi:10.3324/haematol.2012.077917
   PubMed Web of Science ®Google Scholar
• Pang Y, Chihara D. Primary and secondary Central nervous system mature T- and NK-cell lymphomas. Semin Hematol. 2021;58(2):123–129. doi:10.1053/j.seminhematol.2021.02.003
   PubMed Web of Science ®Google Scholar
• Berg SL, Stone J, Xiao JJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004;54(1):85–88. doi:10.1007/s00280-004-0766-5
   PubMed Web of Science ®Google Scholar
• Abid MB, Wang S, Loi HY, et al. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016;95(10):1725–1726. doi:10.1007/s00277-016-2746-3
   PubMed Web of Science ®Google Scholar
• Chihara D, Oki Y, Matsuo K, et al. Incidence and risk factors for Central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. 2011;52(12):2270–2275. doi:10.3109/10428194.2011.596966
   PubMed Web of Science ®Google Scholar
• Chan KL, van der Weyden C, Khoo C, et al. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with Central nervous system involvement. Leuk Lymphoma. 2017;58(4):996–998. doi:10.1080/10428194.2016.1222375
   PubMed Web of Science ®Google Scholar
• Tomlinson SB, Sandwell S, Chuang ST, et al. Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib. Leuk Res. 2019;83:106164. doi:10.1016/j.leukres.2019.05.014
   PubMed Web of Science ®Google Scholar
• Yang H, Li C, Chen Z, et al. Determination of chidamide in rat plasma and cerebrospinal fluid. Regul Toxicol Pharmacol. 2018;98:24–30. doi:10.1016/j.yrtph.2018.07.001
   PubMed Web of Science ®Google Scholar